MedTrace Logo

Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients

NCT04883138 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-01-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.

Conditions

Interventions

DRUG

GIGA-2050

Recombinant Hyperimmune Polyclonal Antibody

Sponsors & Collaborators

  • GigaGen, Inc.

    lead INDUSTRY

Principal Investigators

  • Sean Liu, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2022-01-11
Completion
2022-01-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883138 on ClinicalTrials.gov